发明名称 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
摘要 The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, AbI, DCAMKL1, ABL1, AbI mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS 1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, AxI, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.
申请公布号 US9266890(B2) 申请公布日期 2016.02.23
申请号 US201013143505 申请日期 2010.01.06
申请人 Dana-Farber Cancer Institute, Inc. 发明人 Gray Nathanael S.;Deng Xianming;Kwiatkowski Nicholas P.
分类号 C07D401/12;C07D401/14;C07D487/04;C07D471/14;C07D487/14;C07D491/14;C07D495/14;C07D498/04;C07D513/04 主分类号 C07D401/12
代理机构 Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. 代理人 Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. ;Corless, Esq. Peter F.;Clarke Daniel W.
主权项 1. A compound of formula B: or a pharmaceutically acceptable salt thereof,wherein, R1 iswhich is substituted with 1-4 substituents, selected from alkoxy, R2 is hydrogen or alkyl; R3 is hydrogen or methyl; R4 is hydrogen or methyl; and R6 is hydrogen.
地址 Boston MA US